Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Down 20.1% in August

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) saw a large decline in short interest in August. As of August 15th, there was short interest totalling 33,400 shares, a decline of 20.1% from the July 31st total of 41,800 shares. Approximately 0.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 33,400 shares, the short-interest ratio is presently 1.0 days.

Virpax Pharmaceuticals Stock Performance

VRPX opened at $0.90 on Wednesday. The stock’s fifty day moving average is $0.94 and its 200-day moving average is $0.88. The company has a market capitalization of $10.54 million, a PE ratio of -0.69 and a beta of 2.10. Virpax Pharmaceuticals has a one year low of $0.61 and a one year high of $1.39.

Virpax Pharmaceuticals (NASDAQ:VRPX) last posted its quarterly earnings results on Monday, August 14th. The company reported ($0.27) earnings per share for the quarter.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of Virpax Pharmaceuticals by 4.5% during the 1st quarter. Vanguard Group Inc. now owns 341,977 shares of the company’s stock worth $759,000 after acquiring an additional 14,672 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of Virpax Pharmaceuticals during the 1st quarter worth about $348,000. Finally, Citigroup Inc. acquired a new position in shares of Virpax Pharmaceuticals during the 1st quarter worth about $27,000. Hedge funds and other institutional investors own 6.54% of the company’s stock.

Virpax Pharmaceuticals Company Profile

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.